Endo Unit Shutdown Could Strand Incontinence Treatment Praised By FDA Panel
This article was originally published in Clinica
Astora Women's Health's TOPAS treatment for fecal incontinence seemed headed to market after FDA’s Gastroenterology and Urology Devices Panel unanimously recommended approval on Feb. 25. The mesh implant would be the first device of its kind to treat the difficult and socially isolating condition, which some estimates say affects up to 22% of women older than 60.
You may also be interested in...
Can shaving ever be “friction free”? Not according to Procter & Gamble, which challenged in a complaint to the UK Advertising Standards Authority a claim made by a British cosmetics firm FFS that it provided a “friction free” shaving experience for women via its subscription razor service.
Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.